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Abstract
Head and Neck Squamous Cell Carcinoma (HNSCC) is the fifth most common cancer,
annually affecting over half a million people worldwide. Presently, there are no accepted
biomarkers for clinical detection and surveillance of HNSCC. In this work, a comprehensive
genome-wide analysis of epigenetic alterations in primary HNSCC tumors was employed in
conjunction with cancer-specific outlier statistics to define novel biomarker genes which are
differentially methylated in HNSCC. The 37 identified biomarker candidates were top-scor-
ing outlier genes with prominent differential methylation in tumors, but with no signal in nor-
mal tissues. These putative candidates were validated in independent HNSCC cohorts from
our institution and TCGA (The Cancer Genome Atlas). Using the top candidates, ZNF14,
ZNF160, and ZNF420, an assay was developed for detection of HNSCC cancer in primary
tissue and saliva samples with 100% specificity when compared to normal control samples.
Given the high detection specificity, the analysis of ZNF DNA methylation in combination
with other DNA methylation biomarkers may be useful in the clinical setting for HNSCC
detection and surveillance, particularly in high-risk patients. Several additional candidates
identified through this work can be further investigated toward future development of a
multi-gene panel of biomarkers for the surveillance and detection of HNSCC.
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Introduction
Head and Neck Squamous Cell Carcinoma (HNSCC) affects an estimated 60,000 individuals
in the United States and 600,000 individuals worldwide annually [1, 2]. HNSCC is commonly
caused by tobacco and alcohol exposure, as well as by human papillomavirus (HPV) [1].
Despite advances in the understanding of HNSCC biology, approximately half of all patients
with HNSCC succumb to the disease within five years of diagnosis [2–4].
It is now widely observed that whole-genome hypomethylation, accompanied by gene-spe-
cific promoter hypermethylation, is a general characteristic of solid tumors [5, 6]. Promoter
hypermethylation has been described for an extensive number of genes, and commonly results
in tumor-suppressor gene transcriptional repression [3]. Given the high rate of DNAmethyla-
tion abnormalities in cancerous cells as well as DNAmethylation signal stability during cell
division, the detection of DNA methylation is a valuable tool in the development of biomarkers
for cancer detection and prognosis [7–9]. Several whole-genome methylation assays have been
performed to define the DNAmethylation signature of HNSCC [5, 10–14]. DNAmethylation
of DCC, EDNRB, DAPK, CCNA1, p16,HOXA9 and KIF1A genes have been detected in primary
tissues and biological fluids, including saliva and plasma [7, 10, 15, 16], derived from HNSCC
patients. DNAmethylation of several other genes, includingMINT31,MGMT, NID2, ERCC1,
and TIMP3, have been proposed as biomarkers of HNSCC that can be detected in a patient’s bio-
fluids [11, 16]. Other genes, like CYGB, RASSF1A, SPARC, GSTM1, cyclinA1,MX1,WIF1,
GNG7, CYP1A1, ZNF132, ZNF154, and ZNF447 have demonstrated high rates of DNAmethyla-
tion in primary HNSCC tumors [13, 14, 16–23] and are candidates for further validation of
DNAmethylation detection in body fluids. Genome-wide identification of epigenetically altered
genes in HNSCC enhances an understanding of the mechanisms of carcinogenesis. Additionally,
these approaches can uncover novel cancer-specific DNAmethylation events that can be used
for molecular detection strategies in surgical margins or bodily fluids [7, 24–27].
Recent data suggests that detection of promoter methylation of EDNRB and DCC in patients
with high-risk oral lesions has a similar performance in diagnosis as expert clinical evaluation
[25]. Nonetheless, tests utilizing DCC and EDNRB promoter methylation is limited to 46% sen-
sitivity, and 72% specificity for cancer detection in salivary rinses [25]. While low sensitivity
may be limited by the infrequency of cancer-related changes [11, 25, 28], low specificity raises
technical concerns. Although increasing the test detection threshold can increase specificity
[10, 25], this requires additional cut-off value manipulations that are not practical in the clini-
cal setting. Therefore, detection of novel DNAmarkers with absolute specificity to cancer tis-
sues can improve the current biomarker panels and enhance the potential clinical application
of molecular detection strategies [7, 24–26]. Low sensitivity of individual biomarkers that are
highly specific to cancer tissues can be overcome by combining several highly specific genes
into the panels without sacrificing overall specificity [11].
Given the comprehensive nature of high throughput techniques, thousands of differentially
methylated regions can be detected while comparing tumor and normal samples [10]. The het-
erogeneity of genetic and epigenetic alterations in solid tumors has presented challenges in using
conventional statistical approaches, such as t-tests or signal-to-noise tests. These difficulties can
be minimized by the use of outlier-based analyses to provide a measure of statistical significance
for heterogeneous alterations in tumors. Outlier-based analysis has provided a mechanism to
define significant, but diverse, alterations in cancers. The standard method employed in cancer
research for outlier analysis is Cancer Outlier Profile Analysis (COPA [29]), which compares out-
liers to an empirical null. To eliminate low-signal outliers, this work implemented COPA-based
statistics with a rank sum outlier approach as well as setting a minimum level for the calling of an
outlier [30]. This is the first paper utilizing outlier analysis [30] for biomarker discovery.
Epigenetic Alterations in HNSCC
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Materials and Methods
Tissue samples
Primary tumor tissues and matched salivary rinse samples were collected from HNSCC
patients at Johns Hopkins Hospital after informed, written consent was obtained. This study
was approved by Johns Hopkins Medicine Internal Review Board (JHM IRB) and performed
under research protocol NA_00036235. Overall, two independent cohorts of HNSCC patient
specimens and normal control specimens were used. All human subjects that participated in
this study were de-identified after the clinical data collection. The discovery cohort was com-
posed of 44 primary HNSCC tissues and 25 normal mucosal samples from uvulopalatopharyn-
goplasty (UPPP) surgeries of non-cancer affected control patients from previously published
studies [31–33]. The independent validation cohort included primary tumor tissues and
matched salivary rinse samples from 59 HNSCC patients, 31 normal UPPP tissue samples, and
35 salivary rinse samples from non-cancerous patients. All primary tissue and bodily fluid
specimens were stored at -140°C until use. All primary tissue samples were analyzed by investi-
gators from the Pathology Department of Johns Hopkins Hospital (WHW and JAB). Tumor
samples were confirmed to be HNSCC and were subsequently microdissected to yield at least
75% tumor purity. Clinical characteristics of the two cohorts are listed in S1 and S2 Tables. The
distribution of HNSCC sub-types in both cohorts is representative of the distribution of head
and neck cancer both in the United States and worldwide, including ~30% of HPV-related
(HPV+) oropharyngeal SCC cases. The validity of this discovery cohort, and its suitability for
multiple analyses has been demonstrated in multiple prior publications [31–34]. In an effort to
reduce bias and obtain robust cancer unaffected controls, control patients were randomly
selected from available UPPP tissue specimens and salivary rinses, but clinical characteristics
were not able to be matched.
DNA preparation
Microdissected tumor tissue samples or 250 μl aliquots of saliva samples were digested in 1%
Sodium Dodecyl Sulfate (SDS) solution (Sigma) and 50 μg/ml proteinase K (Invitrogen) solu-
tion at 48°C for 48–72 hours. DNA was purified by phenol-chloroform extraction and ethanol
precipitation as previously described [35]. DNA was resuspended in LoTE buffer, and DNA
concentration was quantified using the NanoDrop spectrophotometer (Thermo Scientific).
RNA preparation
RNA was isolated from the microdissected tissue samples with the mirVana miRNA Isolation
Kit (Ambion) per manufacturer’s recommendations, and RNA concentration was quantified
using the NanoDrop.
Arrays
Ten micrograms of RNA and DNA were submitted to the Johns Hopkins Core Facility for
quality control query and sample analysis by high-throughput arrays. Samples were run on
Affymetrix HuEx1.0 GeneChips (containing 1.4 million probes) for expression analysis and
Illumina Infinium HumanMethylation27 BeadChips (probing 27,578 CpG dinucleotides) for
methylation analysis following bisulfite conversion. All arrays were run according to manufac-
turer protocols and the data was reported earlier [31–33]. Affymetrix Expression Data is avail-
able in GEO33205 and Illumina Methylation Data is available in GEO33202. Both data sets are
available in GEO superSeries GSE33232. The data can be accessed at http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE33232.
Epigenetic Alterations in HNSCC
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HPV analysis
Pathology reports regarding the HPV status of oropharyngeal SCC tumors were obtained from
the Johns Hopkins Hospital Pathology Department. In addition, the HPV status of all oropha-
ryngeal SCC primary tumor tissues was independently confirmed by quantitative PCR (qPCR)
using HPV16 primers and probes on the real-time PCR machine [7] relative to CaSki (ATCC)
cell line, known to have 600 copies of HPV16 per genome. Samples with HPV copy
number 1 copy/genome/cell were identified as HPV positive.
Bisulfite Treatment and Bisulfite Genomic Sequencing
The EpiTect Bisulfite Kit (Qiagen) was used to convert unmethylated cytosines in genomic
DNA to uracil. Bisulfite-treated DNA was amplified with primers designed using MethPrimer
[36, 37] (S3 Table). Primer pairs were designed within the CpG island surrounding the pro-
moter region with close proximity to the methylation array probes. The representative sample
from the discovery cohort were chosen on the basis of highest differences in methylation and
concurrent expression as computed during outlier analysis for each individual gene. Bisulfite
sequencing was chosen for this stage in order to ascertain the absolute (not relative or normal-
ized) methylation status of several CpG dinucleotides in the CpG island near the promoter of
each gene. Touch-down PCR was performed [38]. The PCR products were purified using the
QIAquick 96 PCR Purification Kit (Qiagen) and purified PCR products were sequenced (Gene-
wiz). Gene methylation status was determined as a trichotomous variable (unmethylated,
hemimethylated, or hypermethylated) according to the sequence reads.
Quantitative methylation-specific PCR (QMSP)
For QMSP, primers were designed to specifically include CpG dinucleotides that showed
changes in methylation as seen by bisulfite sequencing. QMSP was performed on the real-time
PCR machine with normalization to unmethylated β-actin reference control [39]. The Taqman
PCR machine was set on 38 cycles maximum to eliminate false-positive signals. Bisulfite-con-
verted leukocyte DNA from a healthy individual was used as a negative control. The relative
level of methylated DNA in each sample was determined as a ratio of the amplified gene to
β-actin [40] and multiplied by 100. Sequences of the primers and probes used can be found in
S3 Table.
Reverse Transcription and Quantitative Real Time PCR
One μg of RNA from the validation cohort was reverse transcribed using the High Capacity
cDNA Reverse Transcription Kit. Quantitative real-time PCR was performed using gene-spe-
cific expression assays (S3 Table) and Universal PCR Master Mix on the 7900HT real-time
PCR machine (all from Applied Biosystems) per manufacturer’s recommendations. Expression
of the gene of interest was quantified in triplicates relative to GAPDH and 18S expression using
the 2-ΔΔCT method [41].
Statistical analysis
Methylation data normalization. For the promoter methylation data, β values (propor-
tion of methylation) were estimated from unmethylated (U) and methylated (M) measure-
ments on a probe level basis. Gene level estimates were produced by choosing the highest
methylation levels among all probes linked to the same gene (14,477 genes total).
Significant core probe determination. Gene expression data was normalized with robust
multi-array average (RMA) analysis using the Bioconductor oligo package [42, 43]. Gene
Epigenetic Alterations in HNSCC
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level estimates were produced by RMA using the core probes, yielding 22,011 genes for analysis
[31, 32].
Outlier Analysis. The standard method employed in cancer research for outlier analysis is
Cancer Outlier Profile Analysis (COPA), which compares the outlier distributions to an empir-
ical null generated by permutation of class labels [29]. A modified rank sum outlier approach,
modified from Ghosh [44], was used, in which minimum change levels were set for the defini-
tion of an outlier [30]. This eliminated many outliers in which change was not biologically
meaningful (e.g., methylation change of less than 10% between any two samples). These statis-
tics were applied to the discovery DNAmethylation data set, containing 14,477 genes for 44
tumor tissues, in which signals from 25 normal samples were used to establish the base line
cut-off point for each gene. Left-tail and right-tail outliers were determined using the rank-sum
method [45]. Outlier scores were calculated for both right-tail and left-tail cases, which allowed
the definition of outliers that were hypermethylated and hypomethylated on tumors, respec-
tively [30, 45]. Given that outlier analysis does not have a score cut-off, a threshold was selected
to yield approximately 50 top-scoring genes. This score cut-off of 13.2 identified 37 top candi-
dates for further validation (S4 Table).
Expression-methylation correlation. Normalized gene expression data was correlated
with promoter methylation levels in the methylation candidates using Spearman’s rank corre-
lation (Table 1).
Correlation and Concordance of DNAMethylation Detection. Correlations of ZNF
DNAmethylation signals between primary tumor tissues and salivary rinses (detected by
QMSP assay) among HNSCC patients from the validation cohort were evaluated via Spear-
man’s coefficient and kappa coefficient. Agreement concordance was calculated using kappa
statistics.
Sensitivity and Specificity Quantitation. The QMSP methylation values for saliva sam-
ples were calculated using a standard curve method and were normalized to a methylation-
independent DNA loading control (β-actin). Methylation level of each gene was treated as a
binary variable (methylated vs. unmethylated) by dichotomizing the methylation at zero DNA
methylation detection by QMSP. Subjects with a diagnosis of HNSCC were defined as “pres-
ence of disease”, and the “absence of disease” subjects were defined by normal controls. True
positive, true negative, false positive and false negative rates were then determined for the indi-
vidual genes. For the combination of markers, the patient was classified as “test positive” if any
of the markers were positive, and “test negative” if all the markers were negative. Sensitivity
was estimated as the proportion of patients who were test positive among those with disease,
and specificity was estimated as the proportion of patients who were test negative among those
without disease. The 95% Confidence Interval (CI) for sensitivity and specificity was calculated
assuming binomial distribution [46].
Results
Identification of differentially methylated gene outliers
From genome-wide differential DNAmethylation analysis of 44 primary tumors and 25 nor-
mal tissue controls, biomarker candidates were selected based on the scheme shown in Fig 1.
Based on the number of outlier samples and the relative signal intensity, 37 of the top ranking
candidates were chosen for further analysis (S4 Table). Correlation of the expression and meth-
ylation array data allowed for the discovery of 24 candidate genes (out of 37 initial genes) with
biologically relevant negative correlation between DNAmethylation and gene expression
(Table 1). Notably, all 24 candidate genes showed hypermethylation and decreased expression
in tumor samples. Furthermore, all candidates showed minimal DNA methylation signal in
Epigenetic Alterations in HNSCC
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normal tissues, with maximal mean of β-value for normal samples of 0.058, or 6% methylation
(S1 Fig and S5 Table). The standard t-test demonstrated that 23 out of 24 genes (96%) had sta-
tistically significant difference in DNAmethylation between normal and all tumor samples
and between normal and HPV- tumor samples. One gene, CCND2, did not reach statistical sig-
nificance based on a t-test, however this did demonstrate a difference between tumor and nor-
mal samples by a Fisher Exact test based on presence of hypermethylated outliers in tumor
samples.
Increased methylation and decreased gene expression alterations in the
HPV- patients
It is known that HPV+ and HPV- HNSCC cases differ in their landscape of genetic and epige-
netic alterations [5, 12, 47, 48]. By separating 44 HNSCC patients by HPV status, it was deter-
mined that 92% (22 of 24) genes had significantly higher methylation in HPV- HNSCC, as
compared to normal samples (S5 Table). Only 4% (1 of 24) candidates had DNAmethylation
in HPV+ HNSCC samples significantly higher relative to normal samples (S5 Table). The
majority, 54% (13 of 24) genes had significantly higher methylation in HPV- HNSCC, as com-
pared to HPV+ samples, in agreement with published data [12]. The tumor samples had a cor-
responding decrease of candidate gene expression (S1 Fig and S6 Table). Thus, 71% (17 of 24)
Table 1. Twenty four DNAmethylation biomarker candidates.
# Gene name Gene description Outlier score Spearman's coefficient p-value
1 HHEX Transcription factor 67.51 -0.079 1.61E-05
2 VILL Villin-like 47.65 -0.235 0.0103
3 CHFR Checkpoint 37.24 -0.464 0.0010
4 ZNF160 Zinc finger 36.21 -0.440 0.0169
5 FLJ22688 (FUZ) Fuzzy homolog 28.08 -0.290 0.0022
6 RBP5 Retinol binding 24.40 -0.123 0.0021
7 MEF2C enhancer 23.48 -0.137 0.0080
8 CLGN Chaperone protein 23.41 -0.135 0.0323
9 IDUA iduronidase 21.79 -0.063 0.0635
10 PIP5K1B kinase 20.68 -0.151 0.0003
11 ADFP (PLIN2) Adipocyte differentiation 19.83 -0.220 0.0117
12 ZNF420 Zinc finger 19.46 -0.280 0.0125
13 ZNF141 Zinc finger 19.02 -0.355 0.0297
14 ZNF211 Zinc finger 17.78 -0.177 0.0118
15 ENPP5 phosphatase 16.47 -0.150 0.0023
16 ZNF71 Zinc finger 16.36 -0.058 0.0039
17 CCND2 Cyclin D2 16.26 -0.014 0.0036
18 GLOXD1 (HPDL) Dioxygenase-like 16.19 -0.16 0.0002
19 ICA1 autoantigen 15.64 -0.327 0.0002
20 ZNF14 Zinc finger 15.45 -0.234 0.0208
21 HAAO dioxygenase 15.41 -0.072 0.0635
22 RECK MMP9 regulator 15.04 -0.222 0.0054
23 ITPKB Inositol kinase 14.61 -0.090 0.0089
24 ZNF585B Zinc finger 14.41 -0.396 0.0017
The genes are ranked by outlier score. Spearman's coefficient was calculated to evaluate DNA methylation and gene expression correlation. P-values for
testing the DNA methylation differences between tumor and normal groups were calculated using t-test
doi:10.1371/journal.pone.0142148.t001
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Fig 1. Integrative methylation screening strategy. Schematic outline of the integrative approach utilized in
this study, which combines high-throughput screening of DNAmethylation and gene expression for the
discovery cohort of HNSCC: employment of DNAmethylation array data with 27,578 probes total;
Epigenetic Alterations in HNSCC
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genes demonstrated a significant decrease in gene expression in all HNSCC samples compared
to normal samples; 75% (18 of 24) genes showed a significant decrease in gene expression in
HPV- samples compared to normal samples; and 21% (5 of 24) genes had significantly
decreased gene expression in HPV- samples compared to HPV+ samples. The decreased gene
expression in tumor samples was consistent with the overall increased promoter methylation
in tumor samples (S1 Fig and Table 1).
Validation of promoter hypermethylation of candidate genes
To validate the differential methylation status of the CpG islands near the promoter region of
the 24 selected candidate genes, bisulfite sequencing was performed on 5 representative sam-
ples of normal mucosal samples and 5 primary HNSCC tumor samples from the initial discov-
ery cohort. Of the 24 genes, 22 (92%) showed increased methylation in tumors relative to
normal samples (Fig 2). Twenty candidate genes (84%) showed methylation in greater than
50% of primary tumor, including ADFP, FUZ, ZNF71, ENPP5, ZNF211, and ZNF14 (Fig 2).
Bisulfite sequencing data strongly correlated with the results from array data, in which minimal
DNAmethylation was detected in normal samples (S1 Fig and Fig 2).
Zinc Finger Protein candidates
It was noted that 7 out of 24 candidate genes were members of the Zinc Finger Protein (ZNF)
group, and additional analysis was performed in this group. In order to elaborate on ZNF can-
didates, DNA methylation was analyzed in a separate validation cohort of 59 tumors and 31
normal tissues (S2 Table). Using bisulfite sequencing methods, significant increase of DNA
methylation for five of the genes was detected in this cohort (S7 Table). However, decreased
DNAmethylation of ZNF141 promoter in the validation cohort contradicted the discovery
cohort data, and, no DNA methylation was detected in ZNF211 in samples from the validation
cohort. Of all remaining five ZNF protein genes, ZNF14, ZNF160, ZNF71, ZNF420 and
ZNF585B, DNAmethylation was significantly higher in tumor samples, as compared to normal
controls (S7 Table).
ZNF downregulation is associated with promoter methylation
To validate the hypothesis that expression of individual ZNF protein genes is affected by meth-
ylation of their promoters, qRT-PCR analysis was subsequently performed for ZNF14, ZNF71,
ZNF160, ZNF420 and ZNF585B expression on the samples from an independent validation
cohort (S2 Fig). All but ZNF71 demonstrated significant downregulation of expression in
tumor samples compared to normal tissues, which was consistent with increased methylation
levels. Separation of tumor samples according to HPV tumor status demonstrated that ZNF
expression was not significantly different in HPV- and HPV+ patient groups (S2 Fig and S7
Table).
normalization of the data in R, 14,477 genes total; outlier analysis and cut-off to receive approximately 50 top
genes (13.2 outlier score; 37 top ranked genes passed, see Methods for details); Integration of the
normalized data from the expression assay (22,011 genes); Spearman’s correlation coefficient calculations
(24 genes passed); 7 ZNFs bisulfite sequencing validation; qRT-PCR, 5 ZNFs gene expression validation;
Validation of 3 ZNF QMSP detection in saliva and tumor samples in different cohorts.
doi:10.1371/journal.pone.0142148.g001
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Fig 2. Promoter DNA hypermethylation of prospective tumor suppressor genes. Bisulfite sequencing results are shown in 5 HNSCC tumor samples
and 5 normal tissues from the original discovery cohort for the 24 top-scoring candidate genes (Table 1). Shaded black boxes represent completely
methylated promoters, gray boxes represent hemimethylated promoters, and white boxes represent unmethylated promoters.
doi:10.1371/journal.pone.0142148.g002
Epigenetic Alterations in HNSCC
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ZNF DNAmethylation detection is highly specific for primary HNSCC
tissues
Based on the DNAmethylation results, it was hypothesized that ZNF methylation could poten-
tially be used as a clinically applicable biomarker for HNSCC. Thus, QMSP primers and probe
assays were designed for ZNF14, ZNF160 and ZNF420. A highly specific QMSP assay for
ZNF585B could not be designed due to its high CpG density.
The QMSP assays were first validated for all three ZNF genes in tissue samples. Similar to
bisulfite sequencing results, QMSP assays did not detect DNA methylation in any normal sam-
ples, but DNAmethylation was detected in ZNF14, ZNF160 and ZND420 in 44.1%, 39% and
32.2% of tumors respectively. At least one ZNF was methylated in 57.6% of tumor tissues.
(Table 2). Notably, 17% of patients (10 of 59) had methylation detected on all three ZNF pro-
moters. Slightly higher rates of DNAmethylation were seen in the HPV- group, but the differ-
ence was not statistically significant (Fig 3).
ZNF DNAmethylation detection in TCGA cohort
To validate ZNF DNAmethylation and its correlation with expression in different HNSCC
cohorts, the Illumina Infinium HumanMethylation450 BeadChip array and RNA-Seq data
were downloaded and analyzed from The Cancer Genome Atlas (TCGA) HNSCC cohort,
which contains 279 HNSCC tumors, including 36 HPV+, with matched normal samples. ZNF
DNAmethylation was minimal in TCGA normal samples (S3 Fig and S10 Table), in agreement
with the discovery and validation cohort data. All three ZNFs had strong negative correlation
of DNA methylation and expression, especially ZNF420 (S3 Fig). Notably, out of all DNA
methylation probes available from TCGA, probes within ZNF420 promoter had the highest
rate of DNAmethylation in HNSCC samples with minimal methylation detection in normal
samples. Overall, we observed a high concordance between the discovery, validation and
TCGA cohorts for the detection of ZNF promoter methylation using four different techniques
for DNAmethylation detection (S9 Table).
ZNF DNAmethylation detection as prospective HNSCC biomarkers
To test the performance of developed QMSP assays for ZNFs for the detection of DNAmethyl-
ation in bodily fluids, matched salivary rinse samples from the HNSCC validation cohort
patients were used. Comparison of DNAmethylation signals in the salivary rinse samples of
HNSCC and non-cancerous patients demonstrated that the specificity of the combined ZNF
panel to detect HNSCC in these bodily fluids was 100% (95% CI: 89.9% - 100%), and the
Table 2. Correlation, concordance and agreement of ZNF DNAmethylation signal in salivary rinses and in primary tissues from the validation
cohort.
Methylated DNA in saliva
(n = 59)
Methylated DNA in tissue
(n = 59)
Methylation level
correlation
Concordance Agreement
n (%) n (%) Spearman correlation (p-
value)
Kappa coefficient (95%
CI)
%
ZNF14 5 (8.5) 26 (44.1) 0.1 (0.4519) 0.14 (-0.03, 0.3) 61.02
ZNF160 10 (16.9) 23 (39) 0.25 (0.0565) 0.25 (0.02, 0.47) 67.8
ZNF420 8 (13.6) 19 (32.2) 0.55 (<0.0001) 0.5 (0.26, 0.73) 81.36
Any
ZNF
13 (22) 34 (57.6) NA 0.28 (0.11, 0.46) 61.02
Significant values are in bold.
doi:10.1371/journal.pone.0142148.t002
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Fig 3. ZNF14, ZNF160, and ZNF420DNAmethylation detection in primary tissues and bodily fluids of
HNSCC patients. Shown are ZNF QMSP results in 59 HNSCC primary tumor and salivary rinse samples
compared to normal plasma and salivary rinse samples from the validation cohort. ZNF promoter methylation
was quantified relative to BACTmethylation and multiplied by 100. Plus (+) or minus (-) refers to their HPV
Epigenetic Alterations in HNSCC
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sensitivity was 22% (95% CI: 12.3% - 34.73%) (Table 3). Notably, the exploration of ZNF meth-
ylation correlation with clinical data by different statistical analyses did not show any signifi-
cant associations.
Discussion
Despite the development of high throughput technologies and the identification of promising
DNAmethylation markers, no one HNSCC biomarker has currently been accepted for clinical
detection and surveillance. A key concern in recently proposed HNSCC biomarkers is the high
false-positive rate. As HNSCC is a highly heterogeneous disease, it is challenging to define a
single biomarker with both high sensitivity and specificity [10, 11, 25]. Many proposed bio-
markers have reasonable sensitivity but relatively low specificity, and combinations of these
biomarkers would likely lead to increased rate of false-positives [25]. Use of conventional sta-
tistical methods may underestimate heterogeneous alterations in malignancy; however, these
challenges can be overcome using recently developed outlier analysis adapted from COPA. To
our knowledge, this is the first published work that utilizes outlier analysis for DNA methyla-
tion biomarker development. While the ZNF group of candidates studied in this work provided
100% specificity, additional studies may boost sensitivity by validating more methylated gene
candidates for the development of a multi-gene DNAmethylation-based panel of HNSCC
biomarkers.
There are a number of publications that utilize high throughput DNAmethylation analysis,
however many have limited cohort sizes [11–13]. This study was able to use a previously pub-
lished cohort consisting of 44 tumor and 25 normal controls for the discovery of potential
methylated biomarkers. Furthermore, biomarkers were additionally validated in a larger inde-
pendent cohort (with 59 tumor samples) and in TCGA (279 tumor samples). The use of the
Illumina 27 DNAmethylation array, which has been used successfully by others [10–14],
allowed for the definition of highly specific prospective biomarkers for HNSCC. However, it is
acknowledged that more comprehensive DNAmethylation platforms may enable the discovery
of larger numbers of candidate alterations.
Correlation of methylation and expression is another powerful tool that was utilized in this
study to identify biologically relevant methylation changes that likely occur earlier in cancer
development [10, 14]. Only methylation changes that occur earlier in tumor development will
allow for development of subsequent gene expression changes. DNA methylation changes that
did not correlate with gene expression were eliminated to define a more focused panel of 24
status of the cancer patients. NS = normal salivary rinse sample (n = 35), N = normal primary tissues (n = 31),
TS = salivary rinse from HNSCC patients (n = 59, 41 of HPV+ [TS+] and 18 of HPV- [TS-]), T = primary tumor
samples from HNSCC patients (n = 59). There was no detectable ZNF DNAmethylation in normal samples.
Significant (p<0.05) difference between groups is indicated by an asterisk (*), as calculated by the Fisher
exact test.
doi:10.1371/journal.pone.0142148.g003
Table 3. Promoter DNA hypermethylation detection in salivary rinses of HNSCC and non-cancerous patients from the validation cohort.
HNSCC (n = 59) Control (n = 35) Sensitivity Specificity Fisher's exact test
n n % (95% CI) % (95% CI) p-value
ZNF14 5 0 8.47 (2.81–18.68) 100 (89.9–100) 0.1534
ZNF160 10 0 16.95 (8.44–28.97) 100 (89.9–100) 0.0119
ZNF420 8 0 13.56 (6.04–24.98) 100 (89.9–100) 0.0237
Any ZNF 13 0 22.03 (12.3–34.73) 100 (89.9–100) 0.0016
doi:10.1371/journal.pone.0142148.t003
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candidate methylated gene biomarkers. Furthermore, correlation of DNA methylation with
expression from the available gene expression array helps to reduce single platform bias. Multi-
ple validation steps were performed in this study which included a total of three cohorts of
HNSCC samples, as well as four different detection techniques for DNA methylation (Illumina
arrays 27 and 450, bisulfite sequencing and QMSP) and three different techniques for gene
expression (Affymetrix array, RNA-Seq from TCGA and qRT-PCR). Consistent results were
observed between different cohorts and techniques (S9 Table). These validation steps con-
firmed high specificity and reliability of the detected ZNF DNA methylation-based biomarkers
for HNSCC.
Higher levels of promoter methylation were observed in HPV- patients in several putative
tumor suppressor genes including Zinc Finger family members, consistent with previously
published reports [12–14]. Significant DNA promoter hypermethylation and decreased gene
expression of ZNF420 were found in HPV- HNSCC patient groups when compared to HPV
+ patients from both discovery and TCGA cohorts (S5 and S6 and S10 and S11 Tables). Differ-
ences between HPV+ and HPV- groups were not observed in ZNF14 and ZNF160, however,
these observations may have been limited by small HPV+ sample size.
Of the 24 biomarker candidates confirmed through expression correlation, seven (29%)
belong to the Zinc Finger protein group, whose members have previously been shown possess
tumor suppressor activity [13]. Additionally, all three prospective biomarkers (ZNF14, ZNF160
and ZNF420) have a KRAB-A domain, and ZNF160 and ZNF420 are found on chromosome
19. Indeed, there are over 800 ZNF genes containing over 8000 ZNF domains in the human
genome [49, 50]. Interestingly, the majority of ZNF gens (266 genes) are found on chromo-
some 19, where 202 of them are KRAB- ZNF genes [49]. The KRAB box-A is a transcription
repression module, which supports the hypothesis that the proposed ZNF candidates are pro-
spective tumor suppressor genes. All but ZNF14 are located on the 19q13 locus, which was
shown to be epigenetically silenced in oropharyngeal cancer [13, 14], supporting the hypothesis
that ZNF160, ZNF420, ZNF585B, and ZNF71 are epigenetically regulated in a coordinated fash-
ion. Consistent with this model, the three prospective ZNF biomarkers were found to be hyper-
methylated in tumor cells with a corresponding decrease in gene expression in both this study
and in the literature [13].
Salivary rinse biomarkers hold promise as inexpensive and non-invasive diagnostic tools
particularly for head and neck malignancies, and have shown sensitivity and specificity compa-
rable to physical examination in selected clinical settings [25]. In this study, the performance of
ZNF DNAmethylation detection was evaluated in both HNSCC primary tissues and salivary
rinses. High correlation and high specificity of ZNF candidates was observed for tissue and
saliva, showing that detection of ZNF DNAmethylation has potential for use in a non-invasive
HNSCC diagnosis assay. The low sensitivity of these biomarkers would require enhancement
by combining these ZNF biomarkers with additional candidate biomarkers either this work or
other similar studies [10, 11, 25]. This combination of highly specific biomarkers has the
potential to lead to the development of a powerful, clinically appropriate diagnostic tool.
There are several limitations of this study that warrant discussion. First, clinical characteris-
tics between normal and tumor patients were not able to be matched, and these clinical differ-
ences may potentially contribute to methylation changes. However, a robust and steady
distribution of DNAmethylation signals for all control samples, regardless of clinical charac-
teristics has been observed in these cohorts, as previously published [31–34]. Moreover, these
analyses were able to be confirmed on the TCGA cohort of matched tumor-normal popula-
tions. Second, the absence of reliable commercial ZNF antibodies for ZNF14, ZNF160 and
ZNF420 limited our ability to confirm the protein level of gene expression during validation
steps. However, expression data were robust enough to confirm the downregulation of
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candidate gene expression in different cohorts. Furthermore, the proposed panel of three ZNF
genes had limited sensitivity in saliva samples. However, our results are comparable to the
most prominent methylation-based HNSCC biomarkers currently available for detection of
HNSCC-specific DNA in saliva: EDNRB (78% specificity and 38% sensitivity) and DCC (88%
specificity and 27% sensitivity) [25]. Despite the lower sensitivity of the ZNF genes relative to
EDNRB and DCC, the 100% specificity of the individual ZNF genes suggests that ZNFs are
promising candidates for HNSCC detection in a combination with ENDRB, DCC, or even with
other candidates from Table 1 and S1 Fig, such asHHEX or FUZ/FLJ22688. In this prospective
combined panel of biomarkers, the exclusive specificity of individual biomarkers towards can-
cer samples will increase the sensitivity of the entire gene panel without sacrificing specificity.
In conclusion, combining multiple high throughput platforms (methylation and gene expres-
sion), use of outlier statistics, and vigorous validation allowed for robust identification of novel
biomarkers for the detection of HNSCC. In addition, ZNF genes were highly represented in
top scoring biomarker candidates and showed consistent hypermethylation in tumors with
corresponding down regulation of gene expression. Furthermore, DNAmethylation changes
in selected ZNF genes (ZNF14, ZNF 160, and ZNF420) are detectable in both tumor and saliva
of HNSCC patients with high specificity and represent promising biomarkers for the develop-
ment of non-invasive assays for the detection and surveillance of HNSCC. Nonetheless, for
these biomarker to be translated to the clinic, further intense pre-clinical evaluation will be
required to define and validate the performance of these biomarkers in the clinical setting.
Supporting Information
S1 Fig. Boxplots for the methylation (β-values, left) and expression (logarithm values of
expression intensity, right) values for the 24 candidate genes from the discovery cohort. B-
values and expression intensity values were from Illumina Infinium HumanMethylation27
BeadChips and Affymetrix HuEx1.0 GeneChips arrays, respectively. HNSCC population was
separated according to their HPV status to HPV- and HPV+ samples. The length of each
box is the inter-quartile range and represents the middle 50% of the values. The horizontal line
inside the box depicts the median. The lower and upper hinges of the box represent the 25th
and 75th percentiles, respectively. The vertical dashed lines extend from the box to the upper
and lower 1.5 inter-quartile values from the upper and lower hinges. The empty circles repre-
sent the outliers above and below the upper and lower hinges. The t-test p-values comparing
group of patients for these 24 genes can be found in S5 and S6 Tables for methylation and
expression values, respectively.
(PDF)
S2 Fig. Expression of ZNFs in the validation cohort. ZNF gene expression is shown relative
to GAPDH. The boxplots were built as described for S1 Fig. Statistical analysis of the data can
be found in S8 Table.
(PDF)
S3 Fig. Boxplots for the methylation (β-values, Illumina Infinium HumanMethylation450
BeadChips, left) and expression (logarithm values of expression intensity, RNA-Seq, right)
of ZNF14 (top), ZNF160 (middle), and ZNF420 (bottom) genes in TCGA cohort. The box-
plots were prepared as in S1 Fig. The t-test p-values comparing groups of patients for these 24
genes can be found in S10 and S11 Tables for methylation and expression values, respectively.
(PDF)
S1 Table. Clinical characteristics of HNSCC patients from the discovery cohort.
(PDF)
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S2 Table. Clinical characteristics of HNSCC patients from the validation cohort.
(PDF)
S3 Table. Primers, probes, and expression assays used in the study.
(PDF)
S4 Table. Outlier scores for 37 candidates from the methylation arrays.
(PDF)
S5 Table. DNAmethylation β-values in different patient groups in the discovery cohort
(Illumina Methylation array 27). These groups were compared by t-test.
(PDF)
S6 Table. Gene expression values in different patient groups in the discovery cohort (Affy-
metrix Exon array). These groups were compared by t-test.
(PDF)
S7 Table. Bisulfite sequencing of the promoter DNA hypermethylation detection in pri-
mary tissues from HNSCC and non-cancerous patients of the validation cohort.
(PDF)
S8 Table. QRT-PCR gene expression values in different patient groups in the validation
cohort. These groups were compared by t-test.
(PDF)
S9 Table. Comparison of the promoter DNA hypermethylation detection in all primary tis-
sues from HNSCC and non-cancerous patients from three cohorts using four different
DNAmethylation detection techniques.
(PDF)
S10 Table. DNAmethylation β-values in different patient groups in the TCGA-HNSCC
cohort (RNA-Seq). These groups were compared by t-test.
(PDF)
S11 Table. Gene expression values in different patient groups in the TCGA-HNSCC cohort
(RNA-Seq). These groups were compared by t-test.
(PDF)
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